Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on December 9, 2025. The filing reports a significant corporate development under Item 8.01 (Other Events) regarding a new research collaboration.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the company's most recent 10-K or 10-Q for financial metrics.
Material Changes and Events
- New Collaboration: The Company announced a research collaboration with The University of Texas MD Anderson Cancer Center.
- Study Focus: The collaboration will examine the use of the Company's nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of thyroid cancers (both benign and malignant).
- Regulatory Status: The Investigational Device Exemption (IDE) for this first-in-human clinical feasibility study has been approved by the FDA.
Outlook, Risks, and Management Commentary
Management, represented by CEO Paul A. LaViolette, highlighted the initiation of this study as a key milestone. The filing incorporates a press release (Exhibit 99.1) detailing the collaboration. No specific financial guidance, risk factors, or contingencies were disclosed in this specific 8-K filing beyond the standard nature of clinical research.
Key Facts for Investor Verification
- Verify the specific terms and duration of the collaboration agreement with MD Anderson Cancer Center.
- Confirm the timeline for the initiation of the first-in-human clinical feasibility study.
- Review the full text of the FDA-approved Investigational Device Exemption (IDE) for scope limitations.
- Check subsequent filings for any financial impact or milestone payments related to this collaboration.